Preclinical system for evaluating topical podofilox treatment of papillomas: dose-response and duration of growth prior to treatment.
The objective of the present study was to assess the utility of Shope rabbit papillomas as an animal model system for studying topical podofilox treatment and to evaluate dose-response relations and influence of duration of papilloma growth prior to treatment. New Zealand White rabbits received inoculations of cottontail rabbit papillomavirus (CRPV) virions of two dilutions at four sites total on the dorsum. Two papillomas on the left side were treated with podofilox (Oclassen Pharmaceuticals, Inc., San Rafael, CA). The drug was given topically twice each day, 5 d per week, for 21 d. We evaluated the effects of drug dose and the duration of papilloma growth prior to treatment. Results indicated that treatment beginning on day 28 with both 0.5 and 2.5% (w/v) podofilox inhibited papilloma growth, but 5.0% was more effective. In a separate experiment, papillomas were treated at 7, 21, or 60 d after virus inoculation. At 7 d, the untreated lesions were latent (not visible). At 21 d after infection, they were about 2.5 mm in diameter. At 60 d, papillomas were about 25 mm. Treatment with 5.0% podofilox beginning on any of those days strongly inhibited papilloma growth. Neither Southern blots nor PCR detected CRPV DNA in cured sites of previous virus infection. Antibody production to CRPV virion was not affected by drug treatment. 5.0% podofilox irritated normal skin adjacent to papillomas as evidenced by inflammation, induration, and superficial erosion. However, healing was satisfactory and no scarring resulted. We concluded that the Shope papilloma was a good model system for studying podofilox treatment because the lesions responded to drug across a broad range of drug concentrations and papilloma sizes.
Kreider
J W
JW
Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Christensen
N D
ND
Christian
C B
CB
Pickel
M D
MD
D000287:Administration, Topical; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D010212:Papilloma / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D012878:Skin Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D011034:Podophyllotoxin